Frazier Life Sciences — Full Portfolio

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

BiotechHealthtechMedical DevicesWestlake Village, US

Todd Franklin Watanabe(Executive Officer, Director)Alexander Asam(Director)RSRicky Sun(Director)

BoardJonathan Silverstein(Director)

Board seatPHPatrick HeronDEDaniel Estes· per SEC Form D

Co-investorsBABain Capital Life SciencesRARA Capital

Collegium Pharmaceutical is a biopharmaceutical company developing a portfolio of medications to treat serious medical conditions.

BiotechCanton, US

MHMichael Heffernan(Executive Officer, Director)inPBPaul Brannelly(Executive Officer)inVKVikram Karnani(President and Chief Executive Officer, and Director)in

BoardEran Nadav(Director)John Freund(Director)

Board seatPHPatrick Heron· per SEC Form D

Co-investorsAPAPERTURE Venture PartnersECEcoR1 CapitalLOLongitude CapitalBOBoston Millennia PartnersRARA Capital

Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.

BiotechHealthtechSan Diego, US

CPChris Peetz(Co-founder & Chief Executive Officer)inEBEric Bjerkholt(Executive Officer)inPRPeter Radovich(Executive Officer)in

BoardMichael Grey(Director)Timothy Walbert(Director)

Board seatPHPatrick HeronPatrick J. Heron· per SEC Form D

Co-investorsCHChiesi VenturesLOLongitude CapitalMEMESA VERDE VENTURE PARTNERSNENew Enterprise Associates (NEA)PAPappas CapitalRIRiverVest Venture Partners+4 more

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

WCWilliam Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)SSStephen Squinto(Executive Officer, Director)in

BoardCGCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Board seatPHPatrick Heron· per SEC Form D

Co-investorsACAccess BiotechnologyFRFrazier Healthcare PartnersLILilly Asia VenturesNENew Leaf Venture PartnersOROrbiMedSPSphera Funds Management+2 more

Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.

BiotechDeep TechHealthtechSouth San Francisco, US

Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Board seatPHPatrick Heron· per SEC Form D

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FOForesite CapitalJAJanus Henderson InvestorsLOLongitude CapitalMEMedicxi+4 more

A Place for Mom is a U.S. and Canadian senior care referral marketplace connecting families with senior living and home care providers.

Vernon Hills, US

Douglas Hirsch(Director)Trevor Bezdek(Co-Chairman & Director)Jonathan Stevens(Executive Officer)Thomas Richards(Executive Officer, Director)Christine Leahy(Executive Officer)Dennis Berger(Executive Officer)

Co-investorsBABain Capital Double Impact Fund LPBABain Capital Life SciencesBABain Capital Tech OpportunitiesBEBessemer Venture PartnersBLBlue Sea CapitalBOBosch Ventures+38 more

Achieve is a specialty pharmaceutical company developing and commercializing cytisinicline as a treatment for nicotine dependence, aimed at helping people who smoke quit.

BiotechHealthtechVancouver, B.C., US

Anthony Clarke(Executive Officer)RSRichard Stewart(Co-founder & Director (former President and CEO))CJCindy Jacobs(Executive Officer, Director)inJXJaime Xinos(Executive Officer)inJBJohn Bencich(Executive Officer, Director)inAndrew D. Goldberg(Chief Executive Officer & Director)in

Co-investorsLILifeSci Venture PartnersVEvenBio PartnersVIVivo Capital

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

JQJohn Quisel(Chief Executive Officer)inJFJean Franchi(Chief Financial Officer)inJYJonathan Yu(Chief Operating Officer)inWSWill Savage(Chief Medical Officer)inPSPamela Stephenson(Chief Commercial Officer)inSCSteve Caffé(Chief Regulatory Officer)in

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesFOForesite CapitalOROrbiMed5A5AM Ventures+7 more

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)GYGary Yeung, CFA(Chief Business Officer)in

BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)

Co-investorsANAndreessen HorowitzARARCH Venture PartnersCOColt VenturesEVEvolution VC PartnersLILifeSci Venture PartnersCICity Hill Ventures+1 more

Fortress Biotech is a biopharmaceutical company that acquires and advances assets across therapeutic areas including oncology, dermatology, and rare diseases, generating value through product revenue, equity holdings, and dividend and royalty income.

BiotechHealthtechMedical DevicesNew York, US

LALindsay A. Rosenwald(Executive Officer, Director)inMSMichael S. Weiss(Director)GAGeorge Avgerinos(Executive Officer)Lucy Lu(Executive Officer)in

BoardEric K. Rowinsky(Director)Dov Klein(Director)

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.

AI & Machine LearningBiotechSouth San Francisco, US

CHCharles Homcy(Director)JCJason Coloma(Chief Executive Officer)in

Co-investorsANAndreessen HorowitzARARCH Venture PartnersFOForesite CapitalGVGV (Google Ventures)HEHercules Capital, Inc.ALAlexandria+9 more

Palvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.

BiotechDigital HealthHealthtechMedical DevicesWayne, US

Wesley H. Kaupinen(President, Chief Executive Officer and Director)Matthew E. Korenberg(Chief Financial Officer, Treasurer and Secretary)inKathleen Goin(Chief Operating Officer)inJeffrey Martini(Chief Scientific Officer)inAKAshley Kline(Chief Commercial Officer)in

Co-investorsBIBioAdvanceSASamsara BioCapitalAGAgent Capital

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPFOForesite CapitalGEGeneral CatalystGVGV (Google Ventures)HBHBM Healthcare Investments+9 more

Scilex Holding Company (Nasdaq: SCLX) acquires, develops, and commercializes non-opioid pain management products for treating acute and chronic pain.

BiotechMedical DevicesPalo Alto, US

Jaisim Shah(Executive Officer, Director)Henry Ji(Executive Officer, Director)Stephen Ma(Executive Officer, Director)David Lemus(Director)

BoardYue Alexander Wu(Director)Jay Chun(Director)

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions.

BiotechHealthtechMedical Devices

BABobak Azamian(Founder)inJeffrey Farrow(Chief Financial Officer and Chief Strategy Officer)Seshadri Neervannan(Chief Operating Officer)AMAziz Mottiwala(Chief Commercial Officer)inDWDianne Whitfield(Chief Human Resources Officer)inEYElizabeth Yeu-Lin(Chief Medical Officer)

Co-investorsAPAPERTURE Venture PartnersFLFlying L PartnersVIVisionary VenturesVIVivo CapitalBABain Capital Life SciencesRTRTW Investments L.P.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc.

BiotechHealthtechNew Haven, US

Thomas Sciascia(Executive Officer)JGJennifer Good(Co-Founder, President and CEO)inTSThomas Sciascia, M.D.(Co-Founder, Chief Scientific Officer)LDLisa Delfini(Executive Officer)inWFWilliam Forbes(Executive Officer)inMichael Heffernan(Director)in

Co-investorsAPAPERTURE Venture PartnersNENew Enterprise Associates (NEA)PIPivotal Life SciencesVIViking GlobalOMOmega Funds

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

GPGrant Pickering(Founder)in

Co-investorsBIBioRock VenturesCTCTI Life Sciences Fund L.P.FOForesite CapitalLOLongitude CapitalPIPivotal Life SciencesRARA Capital+3 more

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

SDSergio Duron(Co-Founder & Chief Executive Officer)inSMSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in

BoardMMMarcos Milla(Director)inJLJay Lichter(Director)inTRTighe Reardon(Executive Officer)

Board seatJames Topper· per SEC Form D

Co-investorsLILightspeed Venture PartnersSASamsara BioCapitalAVAvalon BioVenturesPAPappas CapitalPFPfizer Venture InvestmentsJ.J.P. Morgan Asset Management+1 more

MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases.

BiotechHealthtechCarmel, US

RDRichard DiMarchi(Founder)Peter Kent Hawryluk(Executive Officer, Director)Timothy Knickerbocker(Executive Officer, Director)inSHSteve Hoerter(Chairman & Chief Executive Officer)inSASalomon Azoulay(Chief Medical Officer)inKBKaren Basbaum(Chief Business Officer)in

Board seatPHPatrick Heron· per SEC Form D

Co-investorsNONorwest Venture PartnersIUIU VenturesNENew Enterprise Associates (NEA)OROrbiMedWEWellington ManagementFRFrazier Healthcare Partners

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

TBThomas Baumert(Founder)inMPMark Pruzanski(Chief Executive Officer)inLMLuigi Manenti(Chief Medical Officer)inJFJon Freve(Chief Financial Officer)inBYBryan Yoon(General Counsel and Chief Administrative Officer)inAVAditya Venugopal(Chief Business Officer)in

Co-investorsAVAvego BioScience CapitalBIBioMedPartnersJEJeito CapitalLOLongitude CapitalNONovo HoldingsOROrbiMed+5 more

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.

BiotechDigital HealthMedical DevicesRedwood City, US

ECEmmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRVRobert Vitti(Executive Officer)inOSOliver Stauch(Executive Officer)inCWConrad Wang(Director)in

BoardDEDan Estes(Director)in

Co-investorsHEHealthQuest CapitalVEvenBio PartnersRARA CapitalVEvenBio Global Strategic

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.

BiotechMedical Devices

MPMark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)GWGregory Winter(Co-founder; Nobel Laureate)DCDaniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)

Co-investorsCACambridge Innovation CapitalQIQiming Venture PartnersF-F-Prime CapitalSRSR One Capital Management

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.

BiotechHealthtechMedical Devices

BRBernard Ravina(Founder and Chief Executive Officer)inJDJudy Dunn(President of Research & Development)JFJessica Fees(Chief Financial Officer)inADAriel D. Jasie(Chief Business Officer and General Counsel)inTMTushar Misra(Chief Technical Officer)in

Co-investorsATAtlas VentureACAccess IndustriesACAccess BiotechnologyCACanaan Partners

Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.

BiotechHealthtechMedical DevicesMassachusetts, US

DODaniel Orlando(Chief Executive Officer)inTKTasos Konidaris(Executive Officer)inMartin Paz(Executive Officer)inRobert Gallotto(Executive Officer)inDTDaniel Tasse(Executive Officer, Director)inWilliam Scheinler(Executive Officer)in

Board seatJNJames N. Topper· per SEC Form D

Co-investorsHEHealthQuest CapitalBEBessemer Venture PartnersTHThird Rock Ventures

BiotechWaltham, US

Chris Pacheco(Director)CLCarlos Loya(Executive Officer, Director)in

Board seatLMLauren Mifflin· per SEC Form D · $1.2M raise · filed Mar 2022

Biopharmaceutical company discovering and developing novel biologics, protein, and peptide therapeutics.

BiotechSouth San Francisco, US

Trisha Millican(Director)James Topper(Director)Otello Stampacchia(Director)David Hirsch(Director)Volker Schellenberger(Executive Officer)James Brush(Director)

Board seatJames TopperJWJames W. Brush· per SEC Form D

Co-investorsBABain Capital Life SciencesLOLongitude CapitalVIViking GlobalBLBlackRockCACasdin CapitalFRFranklin Templeton+6 more

BiotechEvanston, US

Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)

BoardLiam Ratcliffe(Director)Terry P. Gould(Director)

Board seatJNJames N. Topper· per SEC Form D

Co-investorsBABain Capital Life SciencesLALatterell Venture PartnersLOLongitude CapitalOUOUP (Osage University Partners)AGAgent CapitalBABain Capital+3 more

Pharmaceutical company developing medicines and vaccines for patient health and treatment.

BiotechHealthtechSan Diego, US

JSJeffrey Stein(Executive Officer, Director)KJKevin Judice(Director)inKevin Forrest(Executive Officer)DTDirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPDPaul Daruwala(Executive Officer)in

Board seatPHPatrick Heron· per SEC Form D

Co-investors5A5AM VenturesAIAisling CapitalBABain Capital Life SciencesRARA CapitalVIVivo CapitalCACanaan Partners+1 more

Cirius Therapeutics is a clinical-stage pharmaceutical company developing therapies for patients with chronic metabolic diseases driven by insulin resistance, including Type 2 Diabetes and obesity.

BiotechDigital HealthGrand Rapids, US

Jerry Callahan(Executive Officer)BFBrian Farmer(Executive Officer)inRobert Baltera(Executive Officer, Director)Howard Dittrich(Executive Officer)

BoardMichael Jandernoa(Director)Mark Olesnavage(Executive Officer)

Board seatDEDaniel Estes· per SEC Form D

Co-investorsFRFrazier Healthcare PartnersNONovo Holdings

Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.

BiotechDigital HealthHealthtechMedical DevicesDublin, US

MWMichael W. Dunne(Executive Officer, Promoter)inCNCorey N. Fishman(Executive Officer, Director, Promoter)inJudith M. Matthews(Executive Officer, Promoter)Jeff Schaffnit(Executive Officer)

BoardBrenton K. Ahrens(Director)Ronald M. Hunt(Director)

Board seatPatrick J. Heron· per SEC Form D · $2.8M raise · filed Jul 2020

Co-investorsBABay City CapitalCACanaan PartnersSOSofinnova VenturesADAdvent Life SciencesDODolby Family VenturesSOSofinnova Venture Partners

HealthtechBelmont, US

Barry Cheskin(Executive Officer, Director)S. Arieh Zak(Executive Officer)George Green(Executive Officer)

BoardDrew Schiff(Director)Michael Carusi(Director)Lou Bock(Director)

Board seatNathan Every· per SEC Form D · $46M raise · filed Jul 2016

Co-investorsAIAisling CapitalARArcher Capital GroupARArcher Venture CapitalLILightstone VenturesJOJohnson & Johnson Innovation – JJDCSCScale Venture Partners

Quanta is a biotech company developing orally bioavailable, CNS-penetrant small-molecule KRAS inhibitors targeting RAS-driven cancers such as pancreatic, colorectal, lung, and endometrial cancers.

BiotechDeep TechHealthtechSouth San Francisco, US

Cameron Pitt(Executive Officer, Director)inDerek Metzger(Executive Officer)

BoardMKMaha Katabi(Director)inPNPerry Nisen(Executive Officer, Director)inRJRajul Jain(Director)in

Board seatMFMaria Fardis· per SEC Form D · $89.1M raise · filed Jun 2026

Co-investorsFIFinchley Healthcare VenturesLOLongitude CapitalSOSofinnova VenturesVIVida VenturesBIBiotechnology Value Fund

Scout Bio developed biotechnology therapies for pets, including a pipeline of monoclonal antibodies and gene therapy programs targeting chronic diseases in companion animals.

AgTechBiotechDeep TechHealthtechPhiladelphia, US

MHMark Hefferman(Executive Officer, Director)

BoardTadataka Yamada(Director)CCCindy Cole(Director)inNancy Hong(Director)

Board seatPatrick HeronAKAditya Kohli· per SEC Form D

Co-investorsCOCompanion FundCOCorrelation VenturesDIDigitalis VenturesRIRiverVest Venture Partners

Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients.

BiotechHealthtechGermantown, US

WLWilliam L. Rust(Executive Officer, Director, Promoter)inCWCarole Welsch(Executive Officer)inGi-Hyeok Yang(Director)Roy Arup(Director)Bernie Treidl(Director)

Board seatJames N. Topper· per SEC Form D

Co-investorsMAMaryland TEDCOTETEDCOJDJDRF T1D Fund

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.

BiotechHealthtechMedical DevicesMenlo Park, US

Jim Bristol(Director)DEDaniel Estes(Director)inSBScott Byrd(Executive Officer, Director)in

Board seatDaniel Estes· per SEC Form D

Co-investorsMOMonograph Capital PartnersPIPICUS CAPITALSASanofi VenturesSVSV Health InvestorsDEDementia Discovery FundFRFrazier Healthcare Partners+2 more

35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.

BiotechHealthtech

Ilia(CEO)Maureen(CSO)

PartnerKLKevin Li· led

Co-investorsVEvenBio PartnersJAJanus Henderson InvestorsVIVivo Capital

Develops novel therapeutics in oncology and autoimmune diseases.

Co-investorsAVAvoro Capital AdvisorsBIBioGeneration VenturesBOBOM

Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.

BiotechDeep TechHealthtechRedwood City, US

Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)

Co-investorsAVAvoro Capital Advisors5A5AM VenturesSASamsara BioCapitalVEVenrock Healthcare Capital PartnersVIVivo Capital

Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.

BiotechPalo Alto, US

James Li(Executive Officer, Director)MFMaria Fardis(Executive Officer, Director)in

BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)JCJill Carroll(Director)in

Co-investorsLOLongitude CapitalOROrbiMedSRSR One Capital Management

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureFOForesite CapitalGEGeneral AtlanticLILifeSci Venture PartnersSCScion Life SciencesTHThe Innovation Space+2 more

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

IGIlan Ganot(CEO)inBMBenit Maru(CMO)MVMatthias Van Woensel(CSO)in

Co-investorsDRDroia VenturesNONovartis Venture FundRVRV Invest GmbHFRFrazier Healthcare PartnersMPMPM BioImpactRTRTW Investments L.P.+1 more

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

FBFrançois Bénard(Founder)KLKuo-Shyan Lin(Founder)DPDavid Perrin(Founder)

Co-investorsANAndreessen HorowitzASAscenta CapitalDEDelos CapitalGEGeneral CatalystLILightspeed Venture PartnersLOLongitude Capital+9 more

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.

BiotechLongevityMedical DevicesBoston, US

Co-investorsWUWUTIF CapitalASAscenta CapitalBIBiotechnology Value FundLILightspeed Venture PartnersLOLongitude CapitalNENextech Invest+1 more

BiotechSeattle, US

MGMitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJPJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)

PartnerJNJames N. Topper· led

Co-investorsDEDecheng CapitalBIBiotechnology Value FundOROrbiMed

Amicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions.

BiotechHealthtechCranbury, US

Daphne Quimi(Executive Officer)JCJohn Crowley(Founder)William D. Baird, III(Executive Officer)

BoardCraig A. Wheeler(Director)Ted W. Love(Director)inMargaret G. McGlynn(Director)

Co-investorsAVAvoro Capital AdvisorsCACanaan PartnersNENew Enterprise Associates (NEA)PRProspect Venture Partners

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

Biotech

Co-investorsASAscenta CapitalOROrbiMedRARA CapitalWEWellington ManagementFRFrazier

Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.

BiotechDeep TechSan Diego, US

JYJin-Quan Yu(Founder)inJin-Quan Yu, Ph.D.(Scientific Founder)BCBen Cravatt Ph.D.(Scientific Founder)Rich Heyman, Ph.D.(Scientific Founder)Angie You, Ph.D.(Chief Executive Officer)

Co-investorsOROrbiMedVIViking Global

Boulder-based biopharmaceutical company developing targeted small molecule cancer drugs; acquired by Pfizer in 2019.

Co-investorsARARCH Venture PartnersRIRidgeback CapitalBOBoulder Ventures

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

ABAndrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inABANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)DMDamien McDevitt(President and Chief Executive Officer)inDMDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)

Co-investorsARARCH Venture PartnersLILifeforce CapitalOROrbiMedDODomain AssociatesEDEDB InvestmentsSESection 32+9 more

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTFTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)ZOZaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsECEcoR1 CapitalILIllumina VenturesNENextech InvestSASanofi VenturesVIVida VenturesGOGoldman Sachs+1 more

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.

BiotechDeep TechHealthtechMedical DevicesLa Jolla, US

Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)inMark E. Davis(Director)TWTroy Wilson(Executive Officer, Director)in

BoardTodd Brady(Director)Michael Martin PhD.(Director)

Co-investorsAVAvoro Capital AdvisorsBRBrace PharmaF-F-Prime CapitalMOMoore Venture Partners

Bluejay is a biotechnology company focused on therapeutic development.

BiotechSan Mateo, US

KCKeting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)

Co-investorsRARA CapitalRIRiverVest Venture PartnersWEWellington ManagementFRFrazier Healthcare PartnersHBHBM Healthcare InvestmentsNONovo Holdings+2 more

Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.

BiotechDigital HealthHealthtechMedical Devices

TMTravis Murdoch, M.D.(Chief Executive Officer and Board Director)in

Co-investorsANAndreessen HorowitzOROrbiMedFOForbion

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support.

BiotechHealthtech

Neil Kumar(Founder)

Co-investorsAIAisling CapitalAMAmzak HealthECEcoR1 CapitalHEHEALTHCARE ROYALTY PARTNERSLOLongwood FundSESequoia Capital+2 more

Calistoga Pharmaceuticals is a pharmaceutical company.

BiotechHealthtechSeattle, US

Co-investorsALAlta PartnersAMAmgen VenturesFRFrazier Healthcare Partners

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.

BiotechMedical DevicesSeattle, US

PIPiers Ingram(President, Co-Founder)inJBJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)

Co-investorsNONovo HoldingsOMOmega FundsJEJeito CapitalNONorwest Venture Partners

cAMPfield is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor for immune-mediated inflammatory diseases, primarily inflammatory bowel disease (ulcerative colitis and Crohn's disease).

BiotechHealthtech

GHGraham Heap(President, Research and Development)inENEzequiel Neimark(Head of Clinical Development)inTSTaylor Spector(Head of Medical Affairs)inSSScott Stirn(Head of CMC)in

Co-investorsLOLongitude Capital

Carmot is a clinical-stage biotechnology company developing novel treatments for obesity and type 2 diabetes through biased receptor agonist compounds.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesBerkeley, US

Daniel A. Erlanson(Executive Officer, Director)Stig K. Hansen(Executive Officer, Director)

BoardTim Kutzkey(Director)Larry Lasky(Director)Aetna Wun Trombley(Director)

Co-investorsHOHorizons VenturesRARA CapitalTCTCG CrossoverTHThe Column Group

Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.

BiotechHealthtechMedical DevicesDurham, US

Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)

Co-investorsAIAisling CapitalALAlta PartnersASAsset Management CompanyCACanaan PartnersPAPappas CapitalSASanderling Ventures

Developed targeted cancer therapies with companion diagnostics (Rubraca); IPO'd in 2011 (NASDAQ: CLVS).

Patrick Mahaffy(Founder)in

Co-investorsAIAisling CapitalNENew Enterprise Associates (NEA)PFPfizer Venture InvestmentsRIRidgeback Capital

Complete Pharmacy Solutions (CPS) provides pharmacy staffing and consulting services to healthcare facilities, offering 24/7 access to licensed pharmacists for medication verification and clinical consultation.

Digital HealthEnterprise SoftwareHealthtechCincinnati, US

Tom Hammons

Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.

BiotechHealthtechMedical DevicesSan Diego, US

JMJames Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in

Co-investorsCACatalys PacificNONovo HoldingsANAN Venture PartnersLILightstone VenturesLOLongwood Fund

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

LLLou Lange(Founder)MLMichael L. Riordan(Founder)inDODaniel O'Dayin

Co-investorsAIAisling CapitalASAsset Management CompanyKLKleiner PerkinsLOLongitude CapitalLULumira VenturesMEMenlo Ventures+5 more

Cyprium Therapeutics develops therapies for rare genetic diseases, with a focus on treatments for Menkes disease.

BiotechDigital HealthHealthtechMedical DevicesNew York, US

Lung Yam(Executive Officer)in

BoardLindsay A. Rosenwald(Director)

Deciphera is a pharmaceutical company focused on developing treatments for people living with cancer.

Biotech

DFDaniel Flynn(Founder)in

Co-investorsNENew Leaf Venture PartnersREREDMILEVIViking Global Investors

Develops selective kinase inhibitors for cancer (QINLOCK); acquired by Ono Pharmaceuticals in 2024.

BiotechWaltham, US

Daniel F. Flynn, Ph.D.(Executive Officer)OROliver Rosen, M.D.(Executive Officer)inThomas Kelly(Executive Officer)MTMichael Taylor(Executive Officer, Director)in

BoardMichael Ross(Director)Liam Ratcliffe, M.D., Ph.D.(Director)

Co-investorsVIViking GlobalREREDMILEVIViking Global Investors

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Alex Lugovskoy(Founder)Michael Gladstone(Founder)

Co-investorsATAtlas VentureECEcoR1 CapitalRARA CapitalRVRV Invest GmbHSASanofi VenturesVIViking Global

Droia Ventures is a specialist venture capital firm investing globally in early-stage drug development companies focused on therapeutics for oncology and genetic disease.

BiotechLeuven, BE

Co-investorsCLClavystBioLILifeArc VenturesNONovo Holdings

GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria.

BiotechHealthtech

Co-investorsAIAisling CapitalPAPatient Square CapitalVIViking Global

Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.

BiotechHealthtechSan Carlos, US

AAAndrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)MHMatthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)

Co-investorsGVGV (Google Ventures)SOSofinnova VenturesTHThe Column GroupREREDMILEVEVersant Ventures

Halda provides AI agents for higher-education enrollment, including a campaign agent for personalized email outreach, a website conversion agent, and an always-on recruiter agent that responds to students via text, email, voice, and WhatsApp.

AI & Machine LearningEdTechSaaSProvo, US

Lance Hydrick(Executive Officer, Director)Dallin Palmer(Director)

BoardSKSid Krommenhoek(Director)in

Co-investorsALAlbum VCKIKickstartRARA Capital

BiotechMedical DevicesNew Haven, US

Scott Phillips(Executive Officer)in

BoardTSTim Shannon(Manager)inLRLiam Ratcliffe(Manager)in

Co-investorsACAccess BiotechnologyCACanaan PartnersCOConnecticut InnovationsELElm Street VenturesRARA CapitalTATaiho Ventures, LLC+1 more

XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding.

BiotechFintech

Co-investorsCACatalys PacificLILightspeed Venture PartnersRARA CapitalSASamsara BioCapitalFRFrazier Healthcare Partners

Hillstar Bio develops precision immunotherapies for autoimmune diseases, using antibody engineering to selectively deplete pathogenic immune cells while sparing healthy ones.

BiotechHealthtech

Co-investorsDRDroia VenturesLILifeArc VenturesFRFrazier Healthcare Partners

Hummingbird Bioscience is a precision biotherapeutics company developing a pipeline of novel targeted therapies for cancer, using proprietary drug discovery technologies and platforms.

AI & Machine LearningBiotechDeep TechHealthtech

PIPiers Ingram(Chief Executive Officer, Co-Founder, Executive Director)inJBJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inKonrad Paszkiewicz(Chief Technology Officer)inKwek Kon Yew(Chief Medical Officer)DTDipti Thakkar(Chief Operating Officer)in

PartnerDEDaniel Estes· led

Co-investorsALAltium CapitalCLClavystBioDEDecheng CapitalDRDroia VenturesKIKiwoom InvestmentMUMuirwoods Ventures+6 more

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.

BiotechHealthtech

Co-investorsHIHighlight CapitalMRMRL Ventures FundXEXeraya CapitalAMAmgen VenturesBLBlackRockBLBlackstone Life Sciences+5 more

Imago Rehab provides at-home rehabilitation for people recovering from neurological or cardiovascular conditions, using one-on-one therapy delivered via telerehabilitation combined with robotic devices, gamification, and an integrated care team.

Digital HealthHealthtechMedical DevicesRoboticsLowell, US

KNKristin Nuckols(Executive Officer)inCJConor James Walsh(Director)Gene Tacy(Executive Officer)Chris Dugan(Executive Officer, Director)inTom Hunter(Executive Officer)

BoardAAArunas A. Chesonis(Director)in

Co-investorsBABantam GroupBEBeacon AngelsLALaunchpad Venture GroupSASafar PartnersWAWalnut Venture Associates

Inipharm is a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting HSD17B13 to treat severe fibrotic liver diseases, including MASH and other conditions with established genetic validation.

BiotechHealthtechMedical Devices

BFBrian Farmer(Co-Founder, Chief Executive Officer)inHeather Hsu, PhD(Co-Founder, Chief Scientific Officer)MGMichael Gallatin, PhD(Co-Founder, SAB Chair)CCChuhan Chung(Chief Medical Officer)in

Co-investors5A5AM VenturesFRFrazier Healthcare PartnersWUWu Capital

Iolyx is a pharmaceutical company focused on developing treatments for ocular conditions.

BiotechMedical Devices

EJElizabeth Jeffords(CEO & President)inENErin Newman(Chief Development Officer)inSDShannon Dahl(Chief Scientific Officer)inBBBryan Boyle(Chief Legal & Administrative Officer)in

Co-investorsALAlumni VenturesFRFrazier Healthcare Partners

Iovance develops TIL (tumor-infiltrating lymphocyte) therapy, a personalized cancer treatment that isolates immune cells from a patient's tumor, expands them in a centralized facility using proprietary manufacturing processes, and returns them for infusion back into the patient.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsAVAvoro Capital Advisors

Jade Biosciences develops therapeutic antibodies targeting autoimmune diseases, with a lead candidate in clinical development for immunoglobulin A nephropathy, a chronic kidney disease.

BiotechHealthtech

Co-investorsFOForesite Capital

KalVista Pharmaceuticals is a global biopharmaceutical company that develops oral therapies for rare diseases, starting with hereditary angioedema (HAE).

BiotechHealthtech

Co-investorsLOLongwood FundRARA Capital

Knipper provides multi-modal pharmaceutical fulfillment and dispensing services, including patient access solutions, pharmacy fulfillment, samples management, and third-party logistics for pharma companies.

Digital HealthHealthtechLogistics & Supply Chain

Co-investorsFRFrazier Healthcare Partners

Krystal Biotech discovers, develops, and commercializes genetic medicines, including gene therapy programs for rare diseases such as dermatological conditions.

BiotechHealthtechMedical DevicesPittsburgh, US

SKSuma Krishnan(President, Research & Development)inKKKrish Krishnan(Chairman & CEO)inDoug Norby(Director)Dino Rossi(Director)

BoardDan Janney(Director)

Co-investorsAVAvoro Capital AdvisorsALAlta Partners

Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.

Biotech

DKDavid King(Co-Founder & CSO)inMFMaria Fardis(CEO)inCCCadmus C. Rich(Chief Medical Officer)inESElaine Stracker(General Counsel)in

Co-investorsALAlta PartnersCACatalio Capital Management, LPDCDC Investment PartnersLOLongitude CapitalLOLongwood FundBIBiotechnology Value Fund+2 more

Acquired by Shire in 2014 (now part of Takeda).

BiotechMedical Devices

Co-investorsLOLongitude CapitalOBOberland CapitalPAPappas CapitalRIRiverVest Venture PartnersSASanofi Ventures

Metagenomi Therapeutics is an in vivo genome editing company that uses genetic material sourced from natural environments (metagenomics) to develop a toolbox of editing tools for deletion, integration, and correction of genetic mutations.

BiotechDeep TechMedical DevicesBerkeley, US

BTBrian Thomas(Founder)inBrian Thomas Jillian Banfield(Founder)Jill Banfield(Founder)

BoardAFAndrew Farquharson(Director)inJak Knowles(Director)

Co-investorsCACatalio Capital Management, LPRARA CapitalSOSozo VenturesAGAgent CapitalHUHumboldtINInCube Ventures+5 more

BiotechDublin 1

Jennifer Schranz(Executive Officer)Axel Bolte(Director)Gary Sender(Executive Officer)Theodore Schroeder(Executive Officer, Director)Robert Crotty(Executive Officer)Colin Broom(Director)

Co-investorsAIAisling CapitalECEcoR1 CapitalLOLongitude CapitalMEMESA VERDE VENTURE PARTNERSNONovartis Venture Fund

NewAmsterdam Pharma develops innovative therapies for cardiovascular disease and lipid-related conditions.

BiotechHealthtechMedical Devices

Co-investorsBABain Capital Life SciencesBIBioGeneration VenturesEQEQT Life SciencesFOForbion

OraPharma develops pharmaceutical products and tools for dental professionals to address oral health concerns, serving dental practices and patients.

HealthtechMedical DevicesBridgewater, US

Co-investorsA-A-Rod CorpCACanaan PartnersHEHealthCapOAOak Investment PartnersDODomain Associates

Pardes Biosciences develops oral medications designed to treat and prevent viral infections, including COVID-19.

BiotechHealthtechSan Francisco, US

ULUri Lopatin(CEO)inUri A. Loptain(Executive Officer, Director)HHHeidi Henson(Executive Officer)inElizabeth Lacy(Executive Officer)Lee Arnold(Executive Officer)

BoardJ. Jay Lobell(Director)

Co-investorsY Y CombinatorFOForesite CapitalKHKhosla Ventures

Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.

BiotechHealthtech

Mr. Basta(CEO)

Co-investorsCACatalys PacificNENew Enterprise Associates (NEA)ASAstellas Venture Management LLCMEMedicxi

BiotechBoston, US

DDDarlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDMDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in

BoardCKChau Khuong(Director)inChristina Takke(Director)Steven Prelack(Director)

Co-investorsRIRidgeback CapitalBIBiotechnology Value FundOROrbiMed

Portola develops research and investigates new targets, modalities, and technologies to address rare disease challenges for patients and their families.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsBLBluebird VenturesLILightstone VenturesPRProspect Venture PartnersKHKhosla VenturesNFNFDG

Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Diego, US

BEBrett Ewald(Chief Operating Officer, Founding Member)inALAlyssa Levin(Chief Financial Officer)inPGPaul Grayson(Chief Executive Officer)in

Co-investors5A5AM VenturesDCDCVC Bio

BiotechMenlo Park, US

BEBrett Ewald(Executive Officer)inUmesh Gangadharmath(Executive Officer)inIMIstvan Molnar(Executive Officer)inYunfei Zhu(Executive Officer)Ana Kusnetzow(Executive Officer)inScott Struthers(Director)

Co-investorsDCDCVC (Data Collective)5A5AM VenturesDCDCVC BioFRFrazier Healthcare PartnersWEWestlake Village BioPartners

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.

BiotechHealthtech

Co-investorsFOForesite CapitalGVGV (Google Ventures)KLKleiner PerkinsMEMedicxiSOSolasta VenturesTHThe Column Group+1 more

Rigel is a biopharmaceutical company that develops and markets therapies including olutasidenib, pralsetinib, and fostamatinib for conditions such as acute myeloid leukemia and chronic immune thrombocytopenia.

BiotechHealthtechSouth San Francisco, US

Raul Rodriguezin

Co-investorsNENew Enterprise Associates (NEA)

Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders.

BiotechDigital HealthMedical Devices

GSGaurav Shah(Co-founder & Chief Executive Officer)in

BoardRoderick Wong(Director)inNYNaveen Yalamanchi(Director)in

Co-investorsAVAvoro Capital AdvisorsBRBroadview VenturesCICivilization Ventures Management, LlcLILifeSci Venture PartnersRTRTW Investments L.P.

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsLILifeArc VenturesOXOxford Science EnterprisesWEWellington ManagementEQEQT Life SciencesFOForbionMOMonograph Capital Partners+1 more

BiotechBoston, US

AFAdam Friedman(Executive Officer, Director)inGGGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)inDSDarrin Stuart(Executive Officer)inErica Jackson(Executive Officer)inAmanda Valentino(Executive Officer)

PartnerKLKevin Li· led

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsECEcoR1 CapitalNENextech InvestVIVida VenturesABAbingworth+3 more

Sorrento Therapeutics is a biotechnology and life sciences company that develops therapeutics and technologies through in-house programs, acquisitions, and mergers.

BiotechDeep TechLongevity

HJHenry Ji(Chairman, President and CEO)Scott Schaus(Chief Technology Officer)

Co-investorsAIAisling CapitalCACanaan Partners

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

BiotechHealthtechMedical DevicesSan Diego, US

EMEric Murphy(Chief Executive Officer, Co-Founder, & Director)in

Co-investorsASAstellas Venture Management LLCDCDCVC (Data Collective)DCDCVC BioLOLongwood FundNONovartis Venture FundOROrbiMed+2 more

A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

BiotechHealthtechMedical DevicesSan Francisco, US

PartnerDEDaniel Estes· led

Co-investorsCACapital Midwest FundLOLongitude CapitalRARA CapitalVIVivo CapitalOXOxford Finance LLC

Sonoma provides a governance platform for enterprise deployments of AI agents built on the Model Context Protocol (MCP), offering a self-service MCP catalog, workflow builder, entitlement policies, audit logging, and security controls such as supply chain scanning and prompt injection protection.

AI & Machine LearningCybersecurityEnterprise Software

SCStephen Cobbe(Founder)in

Co-investorsGOGoAhead VenturesHAHawk Hill Ventures8V8VCALAlexandriaARARCH Venture PartnersLILifeforce Capital

Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.

BiotechHealthtechMedical DevicesSouth San Francisco, US

JBJeffrey Bluestone(Founder)inJBJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)QTQizhi Tang, PhD(Founder and Scientific Advisor)FRFred Ramsdell, PhD(Founder and Scientific Advisor)ARAlexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)

Co-investors8V8VCARARCH Venture PartnersGVGV (Google Ventures)JDJDRF T1D FundLALAVLILifeforce Capital+6 more

SpringWorks is a biotechnology company focused on developing innovative treatments for cancer patients.

BiotechDigital HealthHealthtechMedical DevicesAustin, US

Co-investorsPFPfizer Venture Investments

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

BiotechSouth San Francisco, US

ARAdam Rosenthal(Founder & CEO)inNSNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)SRScott Robertson(Executive Officer)inGary Patou(Executive Officer)in

Co-investorsOROrbiMedRARA CapitalSASanofi VenturesSOSofinnova VenturesVIViking GlobalAGAgent Capital+11 more

BiotechSouth San Francisco, US

Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)

BoardSandra Coufal(Director)DBDavid Bonita(Director)inKVKlaus Veitinger(Director)inRobert Alpern(Director)

Co-investorsAVAvoro Capital AdvisorsLOLongitude CapitalWEWellington ManagementHEHercules Capital, Inc.OROrbiMed

Pfizer is a pharmaceutical company that researches, develops, and manufactures medicines and vaccines to treat and prevent diseases.

BiotechHealthtechNew York City, US

Charles PfizerAlbert Bourlain

Co-investorsANAndera PartnersNENew Enterprise Associates (NEA)